Wow. Nice return but certainly sold AVH too early after a nice low entry. Thought it all happened too fast for comfort with that first surge, every man and his dog seemed to be trading AVH all of a sudden. Well done to those still holding, pricing-in a healthy amount of market penetration now, surely?
2019, one of the more exciting years for bios in recent years. We've got a fair number of companies with key readouts, which should mean some easy momentum trades, leading-in. As always, a bit too much like gambling for me, holding more than punter parcels into trial results, for anything but safety and signs of efficacy/dosing optimisation, which usually means Phase I and 2a. OPT, ANP, PTX, ACW, KZA, DXB, PXS, BOT, all reporting in 2019.
Miscellaneous for 2019.
- BGT if they can secure a much awaited and promoted partnership or commercial arrangement for its flavocide product.
- CYP, possible trade into next round of Fuji signing, though the gap down day was probably the time to capitalise.
- BCT and OCC if they can achieve some strong sales momentum.
Best of luck to all bio hunters this year - should be a ripper!
Disc: I hold OPT, PTX and BGT. Will start adding a few other in the list, shortly.
- Forums
- Commodities
- Biotech Analysts $4M pa
Wow. Nice return but certainly sold AVH too early after a nice...
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online